The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Inhibitor of Human Carbonic Anhydrase II
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Cyclooxygenase-2 (COX-2) is up-regulated in stromal and inflammatory cells. The inducible COX-2 isoform is expressed during inflammation, in some cancers, and in brain tissue after global and focal ischemia. Tissue acidosis is a dominant factor in inflammation, and contributes to pain and hyperalgesia. Recently, compelling epidemiological and clinical evidence has documented the COX-independent effects of some COX-2 inhibitors (i.e., celecoxib, valdecoxib, and rofecoxib); among these effects are carbonic anhydrase (CA) inhibition. Carbonic anhydrases are zinc metalloenzymes expressed in various cell types, including those of the kidney, where they act as general acid–base catalysts. The kidneys are also known to express the highest concentration of COX-2 messenger ribonucleic acid. Celecoxib, like the prototypic CA inhibitor acetazolamide, is structurally characterized by an unsubstituted sulfonamide moiety. In the present study, we report that celecoxib exhibits the characteristics of a potent CA inhibitor, showing inhibitory human carbonic anhydrase II (hCAII) activity in the nanomolar range. Valdecoxib was relatively less potent. Rofecoxib, which lacks the unsubstituted sulfonamide moiety characteristic of CA inhibitors, showed no significant hCAII inhibitory activity. The current study corroborates our earlier report of structure-activity relationships as predictors of such metabolic events as hyperchloremia, acidosis, and changes in calcium and phosphate disposition; and clinical manifestations associated with CA inhibition reported with celecoxib. These data showing inhibition of hCAII by the unsubstituted sulfonamides celecoxib and valdecoxib, but not by rofecoxib, may have important implications for the elucidation of the mechanisms of action as well as the side effects associated with COX-2 inhibitors.
- Eras, J., and M. Perazella. 2001. NSAIDs and the kidney revisited: Are selective cyclooxygenase-2 inhibitors safe? [Review]. Am. J. Med. Sci. 321:181–190. CrossRef
- Mukherjee, D., S. Nissen, and E. J. Topol. 2001. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954–959.
- Smith, W. L., and D. L. DeWitt. 1996. Prostaglandin endoperoxide H synthases-1 and -2 [Review]. Adv. Immunol. 62:167– 215.
- Merck Announces Voluntary Worldwide Withdrawal of Vioxx [News Release]. September 30, 2004. Merck & Co., Whitehouse Station, NJ.
- Pfizer Provides Information to Healthcare Professionals About its Cox-2 Medicine Bextra® (Valdecoxib) [News Release]. October 15, 2004. Pfizer, New York.
- Smith, W. L., R. M. Garavito, and D. L. DeWitt. 1996. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2 [Review]. J. Biol. Chem. 271:33157–33160. CrossRef
- Subongkot, S., D. Frame, W. Leslie, and D. Drajer. 2003. Selective cyclooxygenase-2 inhibition: A target in cancer prevention and treatment [Review]. Pharmacotherapy 23:9–28. CrossRef
- Müller, G. 2003. Medicinal chemistry of target family-directed masterkeys [Review]. Drug Discov. Today 8:681–691. CrossRef
- Knudsen, J. F., G. H. Sokol, and L. R. Cantilena. 2003. Structure-activity relationships as predictors of adverse drug events (ADEs). Clin. Pharmacol. Ther. 73:39 (Abstract).
- Physicians’ Desk Reference, 55th ed., 2001. Medical Economics Company, Montvale, NJ, 2903.
- DuBose, T. D., and L. L. Hamm (eds.). 2002. Acid–Base and Electrolyte Disorders. A Companion to Brenner and Rector’s The Kidney, Saunders, Philadelphia.
- Knudsen, J. F., U. Carlsson, P. Hammarstrüm, G. H. Sokol, and L. R. Cantilena. 2004. Cox-2 inhibitors and carbonic anhydrase activity.Clin. Pharmacol. Ther. 75:44. Abstract.
- Belsky, H. 1953. Use of new oral diuretic, diamox, in congestive heart disease. N. Engl. J. Med. 249:140–143.
- Maren, T. H. 1967. Carbonic anhydrase: Chemistry, physiology, and inhibition [Review]. Physiol. Rev. 47:595–781.
- Beyer, K., and J. Baer. 1961. Physiological basis for the action of newer diuretic agents. Pharmacol. Rev. 40:517– 562.
- Chegwidden, W. R., and N. D. Carter. 2000. Introduction to the carbonic anhydrases. In: The Carbonic Anhydrases. New Horizons, W. R. Chegwidden, N. D. Carter, and Y. H. Edwards, eds. Birkháuser Verlag, Basel, Switzerland, pp. 13–28.
- Hsu, H. H., and B. G. Abbo. 2004. Role of bicarbonate/CO2 buffer in the initiation of vesicle mediated calcification: Mechanisms of aortic calcification related to atherosclerosis. Biochim. Biophys. Acta. 1690:118–123.
- Saini, S. S., D. L. Gessell-Lee, and J. W. Peterson. 2003. The Cox-2 specific inhibitor celecoxib inhibits adenylyl cyclase. Inflammation 27:79–88. CrossRef
- Moore, A. R., and D. A. Willoughby. 1995. The role of cAMP regulation in controlling inflammation [Review]. Clin. Exp. Immunol. 101:387–389.
- Weber, A., A. Casini, A. Heine, D. Kuhn, C. T. Supuran, A.Scozzafava, and G. Klebe. 2004. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: New pharmacological opportunities due to related binding site recognition. J. Med. Chem. 47:550–557. CrossRef
- Rickli, E. E., S. A. Ghazanfar, B. H. Gibbons, and J. T. Edsall. 1964. Carbonic anhydrases from human erythrocytes. Preparation and properties of two enzymes. J. Biol. Chem. 239:1065–1078.
- Freskgård, P. O., U. Carlsson, L. G. Mårtensson, and B. H. Jonsson. 1991. Folding around the C-terminus of human carbonic anhydrase II. Kinetic characterization by use of a chemically reactive SH-group introduced by protein engineering. FEBS Lett. 289:117–122. CrossRef
- Mårtensson, L. G., B. H. Jonsson, P. O. Freskgård, A. Kihlgren, M. Svensson, and U. Carlsson. 1993. Characterization of folding intermediates of human carbonic anhydrase II: Probing substructure by chemical labeling of SH groups introduced by site-directed mutagenesis. Biochemistry 32:224–231. CrossRef
- Zhu, J., X. Song, H. P. Lin, D. C. Young, S. Yan, V. E. Marquez, and C. S. Chen. 2002. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents. J. Natl. Cancer Inst. 94:1745–1757.
- Maderna, P., and C. Godson. 2003. Phagocytosis of apoptotic cells and the resolution of inflammation. Biochim. Biophys. Acta. 1639:141–151.
- McCormack, K., and K. Brune. 1991. Dissociation between the antinociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs. A survey of their analgesic efficacy. Drugs 41:533–547.
- Song, X., H. P. Lin, A. J. Johnson, P. H. Tsang, Y. T. Yang, and S. K. Kulp. 2002. Cyclooxygenase-2, a player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostatic cancer cells. J. Natl. Cancer Inst}. 94:585–591.
- Mori, M., R. J. Staniunas, G. F. Barnard, J. M. Jessup, G. D. Steele Jr., and L. B. Chen. 1993. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology 105:820–826.
- Parkkila, S., A. K. Parkkila, T. Juvonen, V. P. Lehto, and H. Rajaniemi. 1995. Immunohistochemical demonstration of the carbonic anhydrase isoenzymes I and II in pancreatic tumors. Histochem. J. 27:133–138.
- Parkkila, S., H. Rajaniemi, A. K. Parkkila, J. Kivelá, A. Waheed, S. Pastoreková, J. Pastorek, and W. S. Sly. 2000. Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro. Proc. Natl. Acad. Sci. U.S.A. 97:2220–2224. CrossRef
- Puscas, I., M. Coltau, and R. Pasca. 1996. Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action. J. Pharmacol. Exp. Ther. 277:1464–1466.
- Paroutis, P., N. Touret, and S. Grinstein. 2004. The pH of secretory pathways: Measurement, determinants and regulation. Physiology 19:207–215. CrossRef
- The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Inhibitor of Human Carbonic Anhydrase II
Volume 28, Issue 5 , pp 285-290
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- carbonic anhydrase
- Industry Sectors
- Author Affiliations
- 1. Division of Clinical Pharmacology and Medical Toxicology, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
- 4. Box 550, Smithsburg, MD, 21783
- 2. IFM-Department of Chemistry, Linköping University, Linköping, Sweden
- 3. New Hope Cancer Center, Hudson, Florida